ARID1A and neoplasm: In line with this, it has been reported that tumors lacking ARID1A expression exhibit higher tumor-infiltrating lymphocytes (TILs) and enhanced immune checkpoints, which render these tumors sensitive to immune checkpoint blockade therapy (110,111).